GlobeNewswire

Solana Company to Release Third Quarter 2026 Operating Results on November 11, 2026
09/11/2026
PHILADELPHIA, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed digital asset treasury, infrastructure, and services company providing institutional access to [...]
Eos SENOLYTIX’s PTC-2105 Reduced Semaglutide-Associated Lean-Mass Loss in Aged Mice: Data to Be Presented at 19th Sarcopenia, Cachexia & Wasting Disorders International Conference
09/11/2026
Data to highlight PTC-2105’s attenuation of terminal lean-mass decline and semaglutide-associated lean-mass loss in aged mice PTC-2105 is Eos’s lead clinical candidate in development for elderly patients with Sarcopenia [...]
Achieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUIT
09/11/2026
New name and ticker reflect a mission-driven company with one purpose: developing medicine for people who want to quit smoking or vaping. If approved, cytisinicline would be the first new medicine approved by the FDA [...]
Mereo BioPharma Reports Third Quarter 2026 Financial Results
09/11/2026
Ongoing regulatory interactions in collaboration with Ultragenyx on potential path forward for setrusumab in osteogenesis imperfecta (OI) Ongoing FDA interactions in collaboration with Sentynl Therapeutics to refine [...]
R1 and Ascension Extend Partnership Through 2037 Leveraging Phare OS to Advance a Technology-First Revenue Cycle
09/11/2026
Long-term agreement supports Ascension’s efforts to simplify the financial experience for patients, reduce administrative demands, and give care teams more time to focus on those they serve CHICAGO, Nov. 09, 2026 (GLOBE [...]
BioVie Presents New Biomarker Data from the ADDRESS-LC Trial of Bezisterim in Long COVID at the NIH RECOVER-TLC Third Annual Workshop
09/11/2026
New findings from the Phase 2 ADDRESS-LC trial suggest two distinct biomarker-defined Long COVID endotypes 1 associated with different patient responses to bezisterim treatment. Patients with a high-inflammatory [...]
Tectonic Therapeutic to Participate in Upcoming Investor Conferences
09/11/2026
WATERTOWN, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and [...]
Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026
09/11/2026
WILMETTE, Ill., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference
09/11/2026
SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (Nasdaq: ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, today announced that Zhen Li, Ph.D., [...]
Adneuris Therapeutics Reaches Key Regulatory Milestone with FDA Submission of New Drug Application for Cebranopadol in Moderate-to-Severe Acute Pain
09/11/2026
If approved, cebranopadol would be the first dual NOP/MOP receptor (dual-NMR) agonist analgesic available for moderate-to-severe acute pain, introducing a novel mechanism of action to a treatment landscape in need of [...]
AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450
09/11/2026
Submission advances ABP-450 biosimilar development program following recent FDA Type 2b meeting Planned CMAP study designed to generate clinical evidence comparing the neuromuscular activity of ABP-450 and BOTOX ® ; [...]
Neutrolis Doses First Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis in Phase 1b LIBERATE-I Trial of NTR-1011 and Will Present Phase 1a Data at ACR Convergence 2026
09/11/2026
Multi-cohort Phase 1b study evaluating NTR-1011, a first-in-class DNASE1L3 fusion protein designed to degrade Neutrophil Extracellular Traps (NETs), in patients with moderate-to-severe SLE and RA despite standard of [...]
Mentari Therapeutics to Present at Upcoming Investor Conferences
09/11/2026
WALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Mentari Therapeutics, Inc. (Nasdaq: MTRI), a clinical-stage biotechnology company developing therapies for migraine prevention, today announced that members of [...]
Iambic to participate in Jefferies Global Healthcare Conference
09/11/2026
Co-Founder and CEO Tom Miller joins AI drug discovery panel on November 18, 2026 SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Iambic (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel [...]
Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease
09/11/2026
Favorable Early Safety Profile in 18 Patients with No DLTs, IEC-HS, ICANS, GvHD or Grade ≥3 CRS Initial Efficacy Analysis Focused on Skin-Predominant Systemic Sclerosis (SSc/Scleroderma), a Severe Autoimmune Disease [...]
Novastra Therapeutics Reports Further Encouraging Clinical Data for Its Novel XIRT™/OAP Cancer Immune Therapy at SITC 2026
09/11/2026
Preliminary data from an investigator-initiated Phase 1 study reinforce feasibility and suggest upstream innate-to-Th1 proof of mechanism for systematic immune reprogramming therapy (XIRT™) XIRT is built on Novastra’s [...]
Evaxion files amendment to registration statement related to 2025 EIB debt settlement agreement
09/11/2026
COPENHAGEN, Denmark, November 9, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, has filed an amendment to [...]
Tevogen Complements Capital Access with Two-Year Extension to Loan Agreement
09/11/2026
Up to $28.6 million in borrowing capacity through May 2029 WARREN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN ), a healthcare company focused on combining biopharma, [...]
NKGen Biotech to Present Long-Term Follow-Up of Troculeucel in Moderate Alzheimer’s Disease at CTAD 2026
09/11/2026
SANTA ANA, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum